Late adverse events after drug-eluting stent implantation.

Journal Article

Stents that elute antiproliferative drugs prevent restenosis after percutaneous coronary artery revascularization, reducing the need for repeat procedures. Randomized trials in low-risk patients supported initial regulatory approval for drug-eluting stents (DES). In 2006, meta-analyses of long-term outcomes from these trials associated DES use with adverse events, believed to be attributable to late stent thrombosis, occurring more than 9 months after the initial procedure. This article appraises these late adverse effects and illustrates the power and shortcomings of large national registries, focused, well-conducted clinical trials, and meta-analyses of clinical trial data. This timely, robust evidence base reflects an alignment of academic, industry, and public health priorities.

Full Text

Duke Authors

Cited Authors

  • Kong, DF; Eisenstein, EL; Harrington, R

Published Date

  • July 2008

Published In

Volume / Issue

  • 10 / 4

Start / End Page

  • 253 - 262

PubMed ID

  • 18611359

Electronic International Standard Serial Number (EISSN)

  • 1534-3170

Language

  • eng

Conference Location

  • United States